Galectin Therapeutics (GALT) Current Assets (2010 - 2026)

Galectin Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• On a quarterly basis, Current Assets rose 68.99% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $15.7 million, a 68.99% increase from a year earlier, with the FY2025 full-year figure at $19.4 million, up 12.66% from the prior year.
• Current Assets declined to $15.7 million in Q1 2026 per GALT's latest filing, from $19.4 million in the prior quarter.
• Across five years, Current Assets topped out at $33.5 million in Q1 2022 and bottomed at $9.3 million in Q1 2025.
• The 5-year median for Current Assets is $19.6 million (2023), against an average of $21.0 million.
• Across the five-year window, Current Assets slumped 63.53% in 2025 and jumped 68.99% in 2026, its largest moves.
• Year by year, Current Assets stood at $20.6 million in 2022, then soared by 34.83% to $27.7 million in 2023, then plunged by 37.74% to $17.3 million in 2024, then rose by 12.66% to $19.4 million in 2025, then fell by 19.27% to $15.7 million in 2026.
• Per Business Quant, the three latest GALT Current Assets figures stand at $15.7 million (Q1 2026), $19.4 million (Q4 2025), and $12.7 million (Q3 2025).